AQST - Aquestive Therapeutics GAAP EPS of -$0.17 revenue of $12.05M
2024-05-07 17:27:26 ET
- Aquestive Therapeutics press release ( NASDAQ: AQST ): Q1 GAAP EPS of -$0.17.
- Revenue of $12.05M (+8.3% Y/Y).
-
Aquestive's full-year 2024 financial guidance is below....
The Company expects:
Guidance Total revenue (in millions) $48 to $51 Non-GAAP adjusted EBITDA loss (in millions) $22 to $26